Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of JYB1904 versus omalizumab in adults with chronic spontaneous urticaria inadequately controlled by H1 antihistamines
CTR20242434Phase 2Completed
- Sponsor
- Jiangsu Jiye Biopharmaceutical
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ozureprubart in chronic idiopathic urticaria (CIU), sponsored by Jiangsu Jiye Biopharmaceutical. Started Aug 2024; status: completed.
02
Drugs
ozureprubart
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20242434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242434.